Key result
Rosuvastatin added to metformin significantly reduced dehydroepiandrosterone sulfate, total cholesterol, LDL cholesterol, and triglycerides in women with polycystic ovary syndrome.
Why the study?
Does rosuvastatin added to metformin improve endocrine and metabolic parameters in women with polycystic ovary syndrome?
RCT (n=96)
1:1
No
Does rosuvastatin added to metformin improve endocrine and metabolic parameters in women with polycystic ovary syndrome?
The addition of rosuvastatin to metformin significantly improves lipid profiles and DHEAS levels in women with PCOS compared to metformin alone.
Answers are grounded in this paper and cite their sources.
Adding rosuvastatin to metformin improves lipids and DHEAS in PCOS; reinforces statin adjunctive role in this population.
Moreover PCOS also associated with increase cardiovascular risks such as adverse lipid profile and endothelial dysfunction. Recently, statins have been shown to improve endocrine and metabolic aspects of PCOS.Aim of the study:-The aim of this study was to evaluate effects of rosuvastatin as adjuvant therapy in treatment of polycystic ovarian syndrome.Materials and In this study 96 women with PCOS randomly divided equally to two study groups; Group (A) in which patients were allocated to receive metformin (500 mg three times a day) plus rosuvastatin (10 mg/day) and group (B) in which patients were allocated to receive metformin (500 mg three times a day)plus placebo for 12 weeks. Blood samples were obtained before and after treatment for determination of fasting blood sugar, follicle stimulating hormone, luteinizing hormone, Dehydroepiandrosterone sulfate, serum testosterone and total lipid profile. There were a significant decreases observed in both groups with respect to body mass index, fasting blood glucose, testosterones and luteinizing hormone whereas dehydroepiandrosterone sulfate, total cholesterol, low-density lipoprotein cholesterol and triglyceride declined significantly only in Group A.Conclusions:-Rosuvastatin as adjuvant therapy in patients with polycystic ovarian syndrome has many beneficial effects.
No takes yet. Share an insight, caveat, or question.
Al‐Gareeb et al. (2017) conducted an RCT in Polycystic ovary syndrome (PCOS) (n=96). Rosuvastatin vs. Placebo was evaluated on Fasting blood sugar, follicle stimulating hormone, luteinizing hormone, dehydroepiandrosterone sulfate, serum testosterone and total lipid profile. Rosuvastatin added to metformin significantly reduced dehydroepiandrosterone sulfate, total cholesterol, LDL cholesterol, and triglycerides in women with polycystic ovary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: